1)日本血液学会(編):造血器腫瘍診療ガイドライン2023年版.金原出版,東京,2023
2)Vijay A, Gertz MA:Waldenström macroglobulinemia. Blood 109:5096-5103, 2007
3)Lymphoma Study Group of Japanese Pathologists:The World Health Organization classification of malignant lymphomas in Japan:Incidence of recently recognized entities. Pathol Int 50:696-702, 2000
4)Castillo JJ, Advani RH, Branagan AR et al:Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol 7:e827-e837, 2020
5)Merlini G, Baldini L, Broglia C et al:Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 30:211-215, 2003
6)Orellana J, Friedman AH:Ocular manifestations of multiple myeloma, Waldenström's macroglobulinemia and benign monoclonal gammopathy. Surv Ophthalmol 26:157-169, 1981
7)Kudo N, Usui M, Nakabo Y et al:Waldenstrom's macroglobulinemia:a report of two cases, one with severe retinopathy and one with renal failure. Case Rep Hematol 2017:3732902, 2017
8)Baker PS, Garg SJ, Fineman MS et al:Serous macular detachment in Waldenström macroglobulinemia:a report of four cases. Am J Ophthalmol 155:448-455, 2013
9)Chen H, Wang Y, Xu Z et al:Multimodal imaging characteristics and risk factors analysis of Waldenström macroglobulinemia retinopathy. Am J Ophthalmol 253:233-242, 2023
10)Watson JA, Olson DJ, Zhang AY:Hyperviscosity retinopathy due to Waldenström macroglobulinemia:a case report and literature review. J Vitreoretin Dis 5:520-524, 2021
11)原田敬志・徳田浩子・森井一江・他:マクログロブリン血症(Waldenström)における眼底の変化—特に初期症状について.臨眼36:1447-1454,1982
12)Thomas EL, Olk RJ, Markman M et al:Irreversible visual loss in Waldenström's macroglobulinaemia. Br J Ophthalmol 67:102-106, 1983
13)Mansour AM, Arevalo JF, Badal J et al:Paraproteinemic maculopathy. Ophthalmology 121:1925-1932, 2014